tiprankstipranks
Trending News
More News >
Akeso, Inc. (HK:9926)
:9926
Hong Kong Market
Advertisement

Akeso, Inc. (9926) AI Stock Analysis

Compare
32 Followers

Top Page

HK:9926

Akeso, Inc.

(9926)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
HK$128.00
▼(-2.29% Downside)
Akeso, Inc. faces significant challenges with profitability and cash flow, impacting its financial performance score. Technical indicators suggest bearish momentum, while the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score.
Positive Factors
Revenue Growth
Akeso, Inc. has demonstrated a strong revenue growth rate of over 33%, indicating robust demand for its products and potential market expansion.
Gross Margins
Strong gross margins suggest that Akeso, Inc. maintains effective cost control and pricing power, which is crucial for long-term profitability.
Technology Platform
Akeso's proprietary technology platform for antibody drugs positions it well for innovation and competitive advantage in the biopharmaceutical industry.
Negative Factors
Profitability Issues
Ongoing profitability challenges and negative net profit margins highlight operational inefficiencies and the need for improved cost management.
Cash Flow Challenges
Negative cash flow from operations indicates potential liquidity risks and the need for better cash management to support business sustainability.
Leverage and ROE
While leverage is manageable, the negative ROE suggests that Akeso is not generating sufficient returns on equity, impacting shareholder value.

Akeso, Inc. (9926) vs. iShares MSCI Hong Kong ETF (EWH)

Akeso, Inc. Business Overview & Revenue Model

Company DescriptionAkeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
How the Company Makes MoneyAkeso, Inc. generates revenue through the development and commercialization of its proprietary antibody-based therapeutics. The company earns money through the sale of its approved drugs, licensing agreements, and strategic partnerships with other pharmaceutical and biotechnology companies. These collaborations often involve upfront payments, milestone payments, and royalties on sales of successfully developed products. Additionally, Akeso may engage in research and development agreements where it receives funding in exchange for access to its technology platform and expertise in antibody drug development.

Akeso, Inc. Financial Statement Overview

Summary
Akeso, Inc. shows strong gross margins but faces profitability challenges with negative net profit margins and operational inefficiencies. The balance sheet is moderately leveraged, and cash flow issues highlight potential liquidity risks.
Income Statement
45
Neutral
Akeso, Inc. has demonstrated inconsistent revenue growth, with a significant decline from 2023 to 2024. The gross profit margin remains strong, but the company has faced negative net profit margins in recent years, indicating ongoing profitability challenges. The EBIT and EBITDA margins have also been negative, highlighting operational inefficiencies.
Balance Sheet
55
Neutral
The company's balance sheet shows a moderate debt-to-equity ratio, suggesting manageable leverage. Equity ratio is relatively stable, reflecting a balanced asset structure. However, the negative ROE indicates that the company is not currently generating positive returns on equity, posing a risk to shareholder value.
Cash Flow
50
Neutral
Cash flow from operations has been negative in 2024, reflecting challenges in cash generation. Free cash flow has decreased, and the ratio of operating cash flow to net income indicates inefficiencies in cash management. Despite this, the financing cash flow suggests some level of external capital support.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.12B4.53B837.66M225.63M0.00
Gross Profit1.83B4.39B734.54M195.41M-1.90M
EBITDA-604.99M2.17B-1.27B-1.32B-1.01B
Net Income-514.51M2.03B-1.17B-1.07B-1.04B
Balance Sheet
Total Assets12.75B9.18B5.50B4.81B3.86B
Cash, Cash Equivalents and Short-Term Investments7.32B2.40B2.29B2.65B2.80B
Total Debt3.95B2.99B1.88B859.42M198.99M
Total Liabilities6.00B4.66B2.95B1.53B405.73M
Stockholders Equity6.81B4.69B2.64B3.16B3.19B
Cash Flow
Free Cash Flow-1.12B1.59B-2.02B-1.71B-1.06B
Operating Cash Flow-527.62M2.47B-1.24B-1.00B-617.77M
Investing Cash Flow-1.52B-4.00B-889.75M-579.59M-555.70M
Financing Cash Flow3.39B960.89M1.49B1.59B2.88B

Akeso, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price131.00
Price Trends
50DMA
149.87
Negative
100DMA
120.10
Positive
200DMA
94.15
Positive
Market Momentum
MACD
-6.57
Positive
RSI
39.53
Neutral
STOCH
22.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9926, the sentiment is Negative. The current price of 131 is below the 20-day moving average (MA) of 147.42, below the 50-day MA of 149.87, and above the 200-day MA of 94.15, indicating a neutral trend. The MACD of -6.57 indicates Positive momentum. The RSI at 39.53 is Neutral, neither overbought nor oversold. The STOCH value of 22.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9926.

Akeso, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
160.29B34.908.03%16.90%63.11%
68
Neutral
147.91B37.0510.95%1.07%13.69%50.71%
66
Neutral
165.28B131.06-0.72%52.78%0.00%
54
Neutral
46.62B-28.68-21.86%44.21%46.11%
47
Neutral
61.92B-47.00-73.93%47.62%28.72%
45
Neutral
HK$118.83B-14.40%33.46%-7.60%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:9926
Akeso, Inc.
131.00
65.50
100.00%
SBMFF
Sino Biopharmaceutical
1.14
0.72
171.43%
IVBXF
Innovent Biologics
12.60
7.22
134.20%
WXIBF
Wuxi Biologics (Cayman)
5.14
3.50
213.41%
HK:9995
RemeGen Co. Ltd. Class H
103.90
93.18
869.22%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
32.76
22.16
209.06%

Akeso, Inc. Corporate Events

Akeso, Inc. Completes Share Placement, Raises HK$3.49 Billion for R&D
Sep 4, 2025

Akeso, Inc. has successfully completed the placing of new and existing shares, raising approximately HK$3,493.01 million in net proceeds. The funds will primarily be used for global and China R&D of its innovative pipeline, including clinical trials for cancer treatments and the development of next-generation therapeutic technology platforms.

The most recent analyst rating on (HK:9926) stock is a Buy with a HK$177.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

Akeso, Inc. Announces Share Placement to Boost Market Position
Aug 28, 2025

Akeso, Inc. has announced the placement of new and existing shares under a general mandate. The company has entered into an agreement with a placing agent to place 23,550,000 shares at a price of HK$149.54 per share. These shares will be offered to professional, institutional, or other independent investors, ensuring that no single investor becomes a substantial shareholder. This move is expected to enhance Akeso’s financial flexibility and strengthen its market position.

The most recent analyst rating on (HK:9926) stock is a Hold with a HK$158.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

Akeso, Inc. Reports Revenue Growth but Faces Increased Losses in H1 2025
Aug 26, 2025

Akeso, Inc. reported a 37.75% increase in revenue for the first half of 2025, reaching RMB1,411.5 million, driven by a 49.20% rise in commercial sales. Despite the revenue growth, the company experienced a loss of RMB588.3 million, attributed to increased equity investment losses in Summit Therapeutics, higher R&D expenses, and elevated equity incentive costs.

The most recent analyst rating on (HK:9926) stock is a Hold with a HK$158.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

Akeso, Inc. Details Nomination Committee’s Terms of Reference
Aug 26, 2025

Akeso, Inc. has outlined the terms of reference for its Nomination Committee, which was established by the board of directors in April 2020. The committee’s primary role is to identify and recommend suitable candidates for the company’s board of directors and to develop nomination guidelines in compliance with relevant laws and regulations. The committee is composed mainly of independent non-executive directors and is required to meet at least once a year, with provisions for additional meetings as needed. This structure aims to ensure effective governance and strategic leadership within the company.

The most recent analyst rating on (HK:9926) stock is a Hold with a HK$158.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

Akeso, Inc. Schedules Board Meeting for Interim Results Approval
Aug 14, 2025

Akeso, Inc. has announced that its board of directors will meet on August 26, 2025, to consider and approve the interim results for the first half of the year ending June 30, 2025. This meeting is crucial as it will determine the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing its market position.

The most recent analyst rating on (HK:9926) stock is a Buy with a HK$58.97 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025